Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Yuichi J. Shimada(Brigham and Women's Hospital), Michael A. Fifer(Massachusetts General Hospital), Suhny Abbara(The University of Texas Southwestern Medical Center), Jonathan Passeri, James L. Januzzi(Harvard University), Richard D Rothman(Harvard University), Caitlin O’Callaghan(Harvard University), Brian Ghoshhajra(Massachusetts General Hospital), Gia Yannekis(Harvard University), Aaron L. Baggish(University of Lausanne), Carolyn Y. Ho(Brigham and Women's Hospital), Patricia A. Lowry(Harvard University), Christine E. Seidman(Harvard University)
Cited by 135
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k